Trial Profile

A biomarker study of TDP-43 for the treatment of Alzheimer's disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/ciprofloxacin (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Biomarker
Sponsors NeuroSense Therapeutics

Most Recent Events

17 Apr 2023 According to a NeuroSense Therapeutics media release, data are now being evaluated and results from this trial expected by the first week of May.
23 Jan 2023 New trial record
19 Jan 2023 Positive preliminary results published in the NeuroSense Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com